期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

熊果酸对大鼠体内瑞舒伐他汀的药代动力学影响 被引量：3

Effect of Ursolic Acid on Pharmacokinetics of Rosuvastatin in Rats
下载PDF
导出
摘要 目的：探讨熊果酸对大鼠体内瑞舒伐他汀的药代动力学影响。方法12只雄性 SD 大鼠（200～235 g）按随机数字表法分为2组，分别为单用瑞舒伐他汀组与瑞舒伐他汀合用熊果酸组，每组6只，以瑞舒伐他汀100 mg· kg^-1、熊果酸80 mg·kg^-1的剂量灌胃给药，两药合用时先熊果酸后瑞舒伐他汀相继灌胃。采用 LC-MS 测定血药浓度，比较2组间药代动力学参数。结果合用熊果酸后，瑞舒伐他汀药代动力学参数 Cmax、AUC0-t、AUC0-∞参数值分别增加163．02％、145．99％和157．55％，而 CLz/F 值降低了57．84％（P ＜0．05或 P ＜0．01）。结论熊果酸可影响大鼠体内瑞舒伐他汀的药代动力学特性。 Objective To study the effect of ursolic acid on the pharmacokinetics of rosuvasta-tin in rats.Methods Twelve male rats（200-235 g）were randomly given rosuvastatin alone（control group）or in combination with ursolic acid（treatment group）,with 6 rats in each group.Rosuvastatin（100 mg·kg^-1 ）,ursolic acid（80 mg·kg^-1 ）were adiministered by intragastric adminis-tration.Combination of both recipes were adiministered first ursolic acid.LC-MS was used to determine the plasma concentrations of rosuvastatin.Pharmacokinetic parameters were compared between the two groups.Results Compared with control group,Cmax ,AUC0-t and AUC0-∞ parameters were respectively increased by 163.02%,145.99% and 157.55%,but CLz/F was decreased by 57.84% in treatment group（P 〈0.05 or P〈0.01）.Conclusion Ursolic acid can affect the pharmacokinetic properties of rosuvastatin in rats.
作者 温金华 汪安江 邹德琴 赖永全 郑雪莲 熊玉卿
机构地区 南昌大学第一附属医院药剂科 南昌大学临床药理研究所
出处 《南昌大学学报（医学版）》 CAS 2014年第2期1-4,共4页 Journal of Nanchang University：Medical Sciences
基金 国家自然科学基金青年项目(81202583) 江西省教育厅青年基金(GJJ12145)
关键词 熊果酸 瑞舒伐他汀 药代动力学 ursolic acid rosuvastatin pharmacokinetics
分类号 R-332 [医药卫生] R969.1 [医药卫生—药理学]
  • 相关文献

参考文献10

  • 1Liu Jie. Oleanolic acid and ursolic acid: research perspectives[J]. J Ethnopharmacol, 2005,100(1/2) :92-94.
  • 2Hua W J, Hua W X, Fang H J. The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins[J]. Card- iovasc Ther,2012,30(5) :e234-e241.
  • 3Gui C, Obaidat A, Chaguturu R, et al. Development of a cell- based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3[J]. Curt Chem Geuomics, 2010,4 : 1-8.
  • 4Cziraky M J,Willey V J,Mckenney J M,et al. Statin safety:an assessment using an administrative claims database[J]. Am J Cardiol, 2006,97 (SA) : 61 C-68C.
  • 5Soran H, Durrington P. Rosuvastatin : efficacy, safety and clini- cal effectiveness[J]. Expert Opin Pharmacot her, 2008,9 (12) : 2145-2160.
  • 6温文冰,成伙清,刘治军.他汀类药物与其他药物的相互作用[J].中国医院药学杂志,2008,28(4):298-301. 被引量：13
  • 7Neuvonen P J. Drug interactions with HMCr-CoA reductase in- hibitors(statins) : the importance of CYP enzymes, transporters and pharmacogenetics[J]. Curr Opin Investig Drugs, 2010,11 (3) :323-332.
  • 8Pasanen M K, Fredrikson H, Neuvonen P J, et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin[J]. Clin Pharmacol Ther, 2007, 82 (6) : 726-733.
  • 9Choi J H,Lee M G,Cho J Y,et al. Influence of OATP1B1 gen- otype on the pharmacokinetics of rosuvastatin in Koreans[J]. Clin Pharmacol Ther,2008,83(2) :251-257.
  • 10Lu H,Choudhuri S,Ogura K,et al. Characterization of organ- ic anion transporting polypeptide lb2-null mice:essential role in hepatic uptake/toxicity of phalloidin and microcystin- LR[J]. Toxicol Sci, 2008,103(1) :35-45.

二级参考文献30

  • 1Shitara Y, Hirano M, Sato H, et al. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin., analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil[J]. J Pharmacol Exp Ther, 2004, 311 (1) : 228-236.
  • 2Christians U,Jacobsen W,Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reduetase inhibitors in transplant patients:are the statins mechanistically similar[J]. Pharmacol Ther, 1998,80(1 ):1-34.
  • 3Cohen LH,van Leeuwen RE,van Thiel, et al. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes [J]. Biopharm Drug Dispos,2000,21 (9) : 353-364.
  • 4Fujino H,Saito T,Tsunenari Y, et al. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors[J]. Xenobiotica,2004,34(11-12):961-971.
  • 5Andrus MR. Oral anticoagulant drug interactions with statins:case report of fluvastatin and review of the literature[J]. Pharmacotherapy, 2004,24(2): 285-290.
  • 6Ahmad SL. Warfarin interaction[J]. Arch Intern Med, 1990, 150(11) :2407.
  • 7Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors[J]. Am J Cardiol,2004, 94(9) : 1140-1146.
  • 8Kanathur N, Mathai MG, Byrd RP Jr, et al. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis [J]. Tenn-Med,2001, 94(9): 339-341.
  • 9Lewin JJ, Nappi JM, Taylor MH . Rhabdomyolysis with concurrent atorvastatin and diltiazem [J]. Ann Pharmacother, 2002, 36(10): 1546-1549.
  • 10Prueksaritanont T, Zhao JJ, Ma B,et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins[J]. J Pharmacol Exp Ther,2002,301 (3) :1042-1051.

共引文献12

同被引文献28

引证文献3

二级引证文献3

南昌大学学报（医学版）
2014年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部